Process-induced phase transformation of carbamazepine dihydrate to its polymorphic anhydrates

Powder Technology

Volumn 236, Issue , 2013, Pages 114-121

  Khoo, Ji Yi ^a   Shah, Umang V ^a   Schaepertoens, Marc ^a   Williams, Daryl R ^a   Heng, Jerry Y Y ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Drying; Hydrates; Pharmaceuticals; Polymorphs

Indexed keywords

ANHYDRATES; CARBAMAZEPINE; DEHYDRATION PROCESS; DIHYDRATES; IN CONTEXTS; LOW PRESSURES; METASTABILITIES; MINOR COMPONENTS; MOLECULAR MOBILITY; ROLE OF WATER; TEMPERATURE RANGE; VACUUM PRESSURE; WATER OF HYDRATION;

AMIDES; DEHYDRATION; DRUG PRODUCTS; DRYING; ETHANOL; HYDRATES; HYDRATION; NUCLEATION; POLYMORPHISM; VACUUM; VAPORS;

ORGANIC SOLVENTS;

ALCOHOL; CARBAMAZEPINE; ORGANIC SOLVENT; WATER;

ARTICLE; CHEMICAL PHENOMENA; CHEMICAL REACTION; CRYSTALLIZATION; DRUG FORMULATION; DRUG STABILITY; DRUG STRUCTURE; DRUG TRANSFORMATION; HUMIDITY; HYPOBARISM; PHYSICAL CHEMISTRY; PRESSURE; SEPARATION TECHNIQUE; SOLVENT PARTIAL PRESSURE; TEMPERATURE; VACUUM PRESSURE; VAPOR;

EID: 84873743989     PISSN: 00325910     EISSN: 1873328X     Source Type: Journal    
DOI: 10.1016/j.powtec.2012.04.059     Document Type: Article

References (56)

1. Lohani S., Grant D.J.W. Thermodynamics of polymorphs. Polymorphism: In the Pharmaceutical Industry 2006, 21-39. Wiley-Vch Verlag GmbH & Co., Weinheim. R. Hilfiker (Ed.).
2. Grant D.J.W. Polymorphism in Pharmaceutical Solids 1999, vol. 95:1-31. Marcel Dekker, Inc., New York. H.G. Brittain (Ed.).
3. Griesser U.J. The importance of solvates. Polymorphism: In the Pharmaceutical Industry 2006, 211-230. Wiley-VCH Verlag GmbH & Co., Weinheim. R. Hilfiker (Ed.).
4. Taylor L., York P. Characterization of the phase transitions of trehalose dihydrate on heating and subsequent dehydration. Journal of Pharmaceutical Sciences 1998, 87:347-355.
5. Post R.M., Ketter T.A., Uhde T., Ballenger J.C. Thirty years of clinical experience with carbamazepine in the treatment of bipolar illness: principles and practice. CNS Drugs 2007, 21:47-71.
6. Murphy D., Rodríguez-Cintrón F., Langevin B., Kelly R.C., Rodríguez-Hornedo N. Solution-mediated phase transformation of anhydrous to dihydrate carbamazepine and the effect of lattice disorder. International Journal of Pharmaceutics 2002, 246:121-134.
7. Tayel S.A., Soliman I.I., Louis D. Improvement of dissolution properties of carbamazepine through application of the liquisolid tablet technique. European Journal of Pharmaceutics and Biopharmaceutics 2008, 69:342-347.
8. Laine E., Tuominen V., Ilvessalo P., Kahela P. Formation of dihydrate from carbamazepine anhydrate in aqueous conditions. International Journal of Pharmaceutics 1984, 20:307-314.
9. Harris R.K., Ghi P.Y., Puschmann H., Apperley D.C., Griesser U.J., Hammond R.B., Ma C., Roberts K.J., Pearce G.J., Yates J.R., Pickard C.J. Structural studies of the polymorphs of carbamazepine, its dihydrate, and two solvates. Organic Process Research and Development 2005, 9:902-910.
10. Krahn F.U., Mielck J.B. Relations between several polymorphic forms and the dihydrate of carbamazepine. Pharmaceutica Acta Helvetiae 1987, 62:247-254.
11. Li Y.H., Han J., Zhang G.G.Z., Grant D.J.W., Suryanarayanan R. In situ dehydration of carbamazepine dihydrate: a novel technique to prepare amorphous anhydrous carbamazepine. Pharmaceutical Development and Technology 2000, 5:257-266.
12. Rustichelli C., Gamberini G., Ferioli V., Gamberini M.C., Ficarra R., Tommasini S. Solid-state study of polymorphic drugs: carbamazepine. Journal of Pharmaceutical and Biomedical Analysis 2000, 23:41-54.
13. Ceolin R., Toscani S., Gardette M.F., Agafonov V.N., Dzyabchenko A.V., Bachet B. X-ray characterization of the triclinic polymorph of carbamazepine. Journal of Pharmaceutical Sciences 1997, 86:1062-1065.
14. Lowes M.M.J., Caira M.R., Lotter A.P., Vanderwatt J.G. Physicochemical properties and X-ray structural studies of the trigonal polymorph of carbamazepine. Journal of Pharmaceutical Sciences 1987, 76:744-752.
15. Reboul J.P., Cristau B., Soyfer J.C. 5H-Dibenz[b, f]azépinecarboxamide-5 (carbamazépine). Acta Crystallographica 1981, B37:1844-1848.
16. Lang M.D., Kampf J.W., Matzger A.J. Form IV of carbamazepine. Journal of Pharmaceutical Sciences 2002, 91:1186-1190.
17. Kahela P., Aaltonen R., Lewing E., Anttila M., Kristoffersson E. Pharmacokinetics and dissolution of two crystalline forms of carbamazepine. International Journal of Pharmaceutics 1983, 14:103-112.
18. McMahon L.E., Timmins P., Williams A.C., York P. Characterization of dihydrates prepared from carbamazepine polymorphs. Journal of Pharmaceutical Sciences 1996, 85:1064-1069.
19. Grzesiak A.L., Lang M.D., Kim K., Matzger A.J. Comparison of the four anhydrous polymorphs of carbamazepine and the crystal structure of form I. Journal of Pharmaceutical Sciences 2003, 92:2260-2271.
20. Han J., Suryanarayanan R. Applications of pressure differential scanning calorimetry in the study of pharmaceutical hydrates: I. Carbamazepine dihydrate. International Journal of Pharmaceutics 1997, 157:209-218.
21. Strachan C.J., Howell S.L., Rades T., Gordon K.C. A theoretical and spectroscopic study of carbamazepine polymorphs. Journal of Raman Spectroscopy 2004, 35:401-408.
22. Kuhnert-Brandstätter M., Kofler A., Vlachopoulos A. Beitrag zur mikroskopischen Charakterisierung und Identifizierung von Arzneimitteln unter Einbeziehung der UV-Spektrophotometrie. Scientia Pharmaceutica 1968, 36:164-179.
23. Edwards A.D., Shekunov B.Y., Forbes R.T., Grossmann J.G., York P. Time-resolved X-ray scattering using synchrotron radiation applied to the study of a polymorphic transition in carbamazepine. Journal of Pharmaceutical Sciences 2001, 90:1106-1114.
24. Florence A.J., Johnston A., Price S., Nowell H., Kennedy A.R., Shankland N. An automated parallel crystallisation search for predicted crystal structures and packing motifs of carbamazepine. Journal of Pharmaceutical Sciences 2006, 95:1918-1930.
25. Surana R., Pyne A., Suryanarayanan R. Solid-vapour interactions: influence of environmental conditions on the dehydration of carbamazepine dehydrate. AAPS PharmSciTech 2003, 4:68.
26. Dugué J., Céolin R., Rouland J.C., Lepage F. Polymorphism of carbamazepine: solid-state studies on carbamazepine dihydrate. Pharmaceutica Acta Helvetiae 1991, 66:307-310.
27. Kaneniwa N., Yamaguchi T., Watari N., Otsuka M. Hygroscopicity of carbamazepine crystalline powders. Yakugaku Zasshi 1984, 104:184-190.
28. Umeda T., Oshini N., Yokoyama T., Kuroda K., Tatsumi E., Matsuda Y. Kinetics of the thermal transition of carbamazepine polymorphic forms in the solid state. Yakugaku Zasshi 1984, 104:786-792.
29. Otsuka M., Hasegawa H., Matsuda Y. Effect of polymorphic forms of bulk powders on pharmaceutical properties of carbamazepine granules. Chemical and Pharmaceutical Bulletin 1999, 47:852-856.
30. Yoshihashi Y., Yonemochi E., Terada K. Estimation of initial dissolution rate of drug substance by thermal analysis: application for carbamazepine hydrate. Pharmaceutical Development and Technology 2002, 7:89-95.
31. Lang M.D., Grzesiak A.L., Matzger A.J. The use of polymer heteronuclei for crystalline polymorph selection. Journal of the American Chemical Society 2002, 124:14834-14835.
32. Fleischman S.G., Kuduva S.S., McMahon J.A., Moulton B., Walsh R.D.B., Rodriguez-Hornedo N., Zaworotko M.J. Crystal engineering of the composition of pharmaceutical phases: multiple-component crystalline solids involving carbamazepine. Crystal Growth & Design 2003, 3:909-919.
33. Cruz Cabeza A.J., Day G.M., Motherwell S., Jones W. Amide pyramidalization in carbamazepine: a flexibility problem in crystal structure prediction?. Crystal Growth & Design 2006, 6:1858-1866.
34. Cruz Cabeza A.J., Day G.M., Motherwell S., Jones W. Importance of molecular shape for the overall stability of hydrogen bond motifs in the crystal structures of various carbamazepine-type drug molecules. Crystal Growth & Design 2007, 7:100-107.
35. Tian F., Zeitler J.A., Strachan C.J., Saville D.J., Gordon K.C., Rades T. Characterizing the conversion kinetics of carbamazepine polymorphs to the dihydrate in aqueous suspension using Raman spectroscopy. Journal of Pharmaceutical and Biomedical Analysis 2006, 40:271-280.
36. Pohlmann H., Gulde C., Jahn R., Pfeifer S. Polymorphie, Teilchengrobe und blutspiegelwerte von carbamazepin. Pharmazie 1975, 30:709-711.
37. Kipouros K., Kachrimanis K., Nikolakakis I., Malamataris S. Quantitative analysis of less soluble form IV in commercial carbamazepine (form III) by diffuse reflectance Fourier transform spectroscopy (DRIFTS) and lazy learning algorithm. Analytica Chimica Acta 2005, 550:191-198.
38. Kipouros K., Kachrimanis K., Nikolakakis I., Tserki V., Malamataris S. Simultaneous quantification of carbamazepine crystal forms in ternary mixtures (I, III, and IV) by diffuse reflectance FTIR spectroscopy (DRIFTS) and multivariate calibration. Journal of Pharmaceutical Sciences 2006, 95:2419-2431.
39. Cruz Cabeza A.J., Day G.M., Motherwell S., Jones W. Solvent inclusion in form II carbamazepine. Chemical Communications 2007, 1600-1602.
40. Getsoian A., Lodaya R.M., Blackburn A.C. One-solvent polymorph screen of carbamazepine. International Journal of Pharmaceutics 2008, 348:3-9.
41. Ostwald W.Z. The formation and changes of solids. Zeitschrift für Physikalische Chemie 1897, 22:289-330.
42. Han J., Suryanarayanan R. Influence of environmental conditions on the kinetics and mechanism of dehydration of carbamazepine dihydrate. Pharmaceutical Development and Technology 1998, 3:587-596.
43. Khoo J.Y., Williams D.R., Heng J.Y.Y. Dehydration kinetics of pharmaceutical hydrate: effects of environmental conditions and crystal forms. Drying Technology 2010, 28:1164-1169.
44. Khoo J.Y., Heng J.Y.Y., Williams D.R. Agglomeration effects on the drying and dehydration stability of pharmaceutical acicular hydrate: carbamazepine dihydrate. Industrial and Engineering Chemistry Research 2010, 49:422-427.
45. Zhang G., Law D., Schmidt A.C., Qiu Y. Phase transformation considerations during process development and manufacture of solid oral dosage forms. Advanced Drug Delivery Reviews 2004, 56:371-390.
46. Nordhoff S., Ulrich J. Solvent-induced phase transformations of hydrates. Journal of Thermal Analysis and Calorimetry 1999, 57:181-192.
47. Gu C., Young V.G., Grant D.J.W. Polymorph screening: influence of solvents on the rate of solvent-mediated polymorphic transformation. Journal of Pharmaceutical Sciences 2001, 90:1878-1890.
48. Cardew P.T., Davey R.J. The kinetics of solvent-mediated phase transformations. Proceedings of the Royal Society of London. Series A 1985, 398:415-428.
49. Garnier S., Petit S., Coquerel G. Dehydration mechanism and crystallisation behaviour of lactose. Journal of Thermal Analysis and Calorimetry 2002, 68:489-502.
50. Lee T., Su Y.C., Hou H.J., Hsieh H.Y. Initial solvent screening of carbamazepine, cimetidine, and phenylbutazone: part 1 of 2. Pharmaceutical Technology 2009, 33:62-72.
51. Liu W., Dang L., Black S., Wei H. Solubility of carbamazepine (Form III) in different solvents from (275 to 343)K. Journal of Chemical & Engineering Data 2008, 53:2204-2206.
52. Behme R.J., Brooke D. Heat of fusion measurement of a low melting polymorph of carbamazepine that undergoes multiple-phase changes during differential scanning calorimetry analysis. Journal of Pharmaceutical Sciences 1991, 80:986-990.
53. Vogt F.G., Dell'Orco P.C., Diederich A.M., Su Q., Wood J.L., Zuber G.E., Katrincic L.M., Mueller R.L., Busby D.J., DeBrosse C.W. A study of variable hydration states in topotecan hydrochloride. Journal of Pharmaceutical and Biomedical Analysis 2006, 40:1080-1088.
54. Bakhshi A., Mohammadia T., Nikb O.G., Aroujalian A. Effect of operating conditions on pervaporation of methanol-water mixtures: part 2. Membrane Technology 2006, 12:7-11.
55. Shao Q., Huang L., Zhou J., Lu L., Zhang L., Lu X., Jiang S., Gubbins K.E., Zhu Y., Shen W. Molecular dynamics study on diameter effect in structure of ethanol molecules confined in single-walled carbon nanotubes. Journal of Physical Chemistry C 2007, 111:15677-15685.
56. Ji Yi Khoo, Thermodynamic stability and kinetic analysis of pharmaceutical channel hydrate during dehydration process, PhD Thesis, Imperial College London, London, 2010, pp. 154-202.